Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects

Journal of Clinical Investigation

Volumn 109, Issue 12, 2002, Pages 1607-1615

  Yang, Yu An ^a   Dukhanina, Oksana ^a   Tang, Binwu ^a   Mamura, Mizuko ^a   Letterio, John J ^a   MacGregor, Jennifer ^a   Patel, Sejal C ^a   Khozin, Shahram ^a   Liu, Zi Yao ^a   Green, Jeffrey ^a   Anver, Miriam R ^b   Merlino, Glenn ^a   Wakefield, Lalage M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR TRANSFORMING GROWTH FACTOR BETA2 RECEPTOR FUSION PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; ENHANCER REGION; FEMALE; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM;

ANIMALS; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; LIVER NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0036087521     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200215333     Document Type: Article

References (47)

1. The transforming growth factors-β
2. TGF-β signaling in tumor suppression and cancer progression
3. TGFβ signaling in growth control, cancer, and heritable disorders
4. Role of transforming growth factor-β signaling in cancer
5. TGF-β and cancer
6. TGF-β in the cardiovascular system: Molecular mechanisms of a context-specific growth factor
7. Manipulation of TGF-β to control autoimmune and chronic inflammatory diseases
8. TGF-β and fibrosis
9. TGF-β in infections and infectious diseases
10. The role for transforming growth factor-β (TGF-β) in human cancer
11. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease
12. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β 1
13. A soluble transforming growth factor β receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats
14. Gene therapy by transforming growth factor-β receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis
15. Recombinant soluble transforming growth factor β type II receptor ameliorates radiation enteropathy in mice
16. Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters
17. Transforming growth factor β 1 null mutation in mice causes excessive inflammatory response and early death
18. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease
19. Transforming growth factor β1 suppresses non-metastatic colon cancer at an early stage of tumorigenesis
20. Chimeric extracellular domain type II transforming growth factor (TGF)-β receptor fused to the Fc region of human immunoglobulin as a TGF-β antagonist
21. Soluble cytokine receptors: Novel immunotherapeutic agents
22. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
23. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene
24. Immunodetection and quantitation of the two forms of transforming growth factor-β (TGF-β 1 and TGF-β 2) secreted by cells in culture
25. Reduction in transforming growth factor-β type II receptor in mouse lung carcinogenesis
26. Disassociation of met-mediated biological responses in vivo: The natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis
27. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo
28. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression
29. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor β antibody and interleukin-2
30. Anti-(transforming growth factor β) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice
31. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
32. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease
33. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor βII receptor
34. SLE-like auroantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-β knockout mice
35. Autoimmunity associated with TGF-β1-deficiency in mice is dependent on MHC class II antigen expression
36. Genetic and immunologic determinants of age-related and virus-induced cardiopathy
37. Immunocytochemical localization of secreted transforming growth factor-β 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma
38. Elevated plasma transforming growth factor-β 1 levels in breast cancer patients decrease after surgical removal of the tumor
39. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency
40. Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development
41. Latent transforming growth factor-β structural features and mechanisms of activation
42. Transforming growth factor-β and breast cancer: Mammary gland development
43. Aberrant TGF-β production and regulation in metastatic malignancy
44. Distribution and modulation of the cellular receptor for transforming growth factor-β
45. Critical steps in hematogenous metastasis: An overview
46. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells